Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

COUNTER-compliant statistics provided by IRUS-UK.
Unless otherwise indicated, items in Spiral are protected by copyright and are licensed under a Creative Commons Attribution NonCommercial NoDerivatives License.